Open an account

Lipocine

LPCN · NASDAQ

$1.62+$0.09 (+5.88%)TodayMarket closed ·
Prev close $1.53

About LPCN

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 14 full-time employees. The company went IPO on 2014-03-21. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. The company is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.

Employees
14
Headquarters
Salt Lake City, Utah
Listed
Mar 21, 2014
Sector
Health Care
Industry
Pharmaceuticals
Website
lipocine.com

LPCN key statistics

Market cap
13.36M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.61M
Volume
219.03K
Open price
$1.54
High today
$1.66
Low today
$1.54
52 Week high
$12.37
52 Week low
$1.40

Lipocine (LPCN) at a glance

Lipocine (LPCN) last traded at $1.62, with a market cap of 13.36M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.54 and $1.66. The current price is 5.4% above the day's low and 2.4% below its high.

Volume so far is 219.03K shares, below the average of 5.61M shares a day.

Over the past year Lipocine has ranged from $1.40 to $12.37, and now sits 2% of the way up that range.

Lipocine met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.32 per share against an estimate of -$0.4437.

The average analyst price target is $5.10, 214.8% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 4 analystsAvg $5.10
Low
$4.04
Now
$1.62
High
$6.30

LPCN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 127.1% on average.

  1. Q3 FY24: reported -$0.41 per share against an estimate of -$0.4947
  2. Q4 FY24: reported $1.86 per share against an estimate of -$0.408
  3. Q1 FY25: reported -$0.35 per share against an estimate of -$0.357
  4. Q2 FY25: reported -$0.41 per share against an estimate of -$0.408
  5. Q3 FY25: reported -$0.59 per share against an estimate of -$0.5508
  6. Q4 FY25: reported -$0.42 per share against an estimate of -$0.6222
  7. Q1 FY26: reported -$0.54 per share against an estimate of -$0.4947
  8. Q2 FY26: reported -$0.32 per share against an estimate of -$0.4437

LPCN news

  • Avi Kapoor

    Nasdaq Falls Over 100 Points; US Crude Inventories Decline

  • Vandana Singh

    Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada

  • Avi Kapoor

    Dow Tumbles 350 Points; Constellation Brands Earnings Top Views

  • Press releasePRNewswire

    Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy

  • Press releasePRNewswire

    Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

  • Press releasePRNewswire

    Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releasePRNewswire

    Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

  • Press releasePRNewswire

    Lipocine Appoints Michael J. Grissinger to Board of Directors

Similar companies

Companies in the same industry as Lipocine

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.